Literature DB >> 32016082

A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer.

Daniel Hyuck-Min Kwon1,2, Terence Friedlander1,2.   

Abstract

Entities:  

Year:  2019        PMID: 32016082      PMCID: PMC6976495          DOI: 10.21037/atm.2019.09.21

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  17 in total

1.  Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Authors:  Fred Saad; David Cella; Ethan Basch; Boris A Hadaschik; Paul N Mainwaring; Stéphane Oudard; Julie N Graff; Kelly McQuarrie; Susan Li; Stacie Hudgens; Joe Lawson; Angela Lopez-Gitlitz; Margaret K Yu; Matthew R Smith; Eric J Small
Journal:  Lancet Oncol       Date:  2018-09-10       Impact factor: 41.316

2.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Authors:  Ian D Davis; Andrew J Martin; Martin R Stockler; Stephen Begbie; Kim N Chi; Simon Chowdhury; Xanthi Coskinas; Mark Frydenberg; Wendy E Hague; Lisa G Horvath; Anthony M Joshua; Nicola J Lawrence; Gavin Marx; John McCaffrey; Ray McDermott; Margaret McJannett; Scott A North; Francis Parnis; Wendy Parulekar; David W Pook; M Neil Reaume; Shahneen K Sandhu; Alvin Tan; T Hsiang Tan; Alastair Thomson; Emily Tu; Francisco Vera-Badillo; Scott G Williams; Sonia Yip; Alison Y Zhang; Robert R Zielinski; Christopher J Sweeney
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

3.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Kim N Chi; Neeraj Agarwal; Anders Bjartell; Byung Ha Chung; Andrea J Pereira de Santana Gomes; Robert Given; Álvaro Juárez Soto; Axel S Merseburger; Mustafa Özgüroğlu; Hirotsugu Uemura; Dingwei Ye; Kris Deprince; Vahid Naini; Jinhui Li; Shinta Cheng; Margaret K Yu; Ke Zhang; Julie S Larsen; Sharon McCarthy; Simon Chowdhury
Journal:  N Engl J Med       Date:  2019-05-31       Impact factor: 91.245

4.  Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Authors:  Matthew R Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A Hadaschik; Julie N Graff; David Olmos; Paul N Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez-Gitlitz; Géralyn C Trudel; Byron M Espina; Youyi Shu; Youn C Park; Wayne R Rackoff; Margaret K Yu; Eric J Small
Journal:  N Engl J Med       Date:  2018-02-08       Impact factor: 91.245

5.  A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.

Authors:  Niranjan J Sathianathen; Fernando Alarid-Escudero; Karen M Kuntz; Nathan Lawrentschuk; Damien M Bolton; Declan G Murphy; Simon P Kim; Badrinath R Konety
Journal:  Eur Urol Oncol       Date:  2019-01-30

6.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

7.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

8.  Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Authors:  Russell Z Szmulewitz; Cody J Peer; Abiola Ibraheem; Elia Martinez; Mark F Kozloff; Bradley Carthon; R Donald Harvey; Paul Fishkin; Wei Peng Yong; Edmund Chiong; Chadi Nabhan; Theodore Karrison; William D Figg; Walter M Stadler; Mark J Ratain
Journal:  J Clin Oncol       Date:  2018-03-28       Impact factor: 50.717

9.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

10.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Authors:  M R Sydes; M R Spears; M D Mason; N W Clarke; D P Dearnaley; J S de Bono; G Attard; S Chowdhury; W Cross; S Gillessen; Z I Malik; R Jones; C C Parker; A W S Ritchie; J M Russell; R Millman; D Matheson; C Amos; C Gilson; A Birtle; S Brock; L Capaldi; P Chakraborti; A Choudhury; L Evans; D Ford; J Gale; S Gibbs; D C Gilbert; R Hughes; D McLaren; J F Lester; A Nikapota; J O'Sullivan; O Parikh; C Peedell; A Protheroe; S M Rudman; R Shaffer; D Sheehan; M Simms; N Srihari; R Strebel; S Sundar; S Tolan; D Tsang; M Varughese; J Wagstaff; M K B Parmar; N D James
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976

View more
  4 in total

1.  Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.

Authors:  Shintaro Narita; Takahiro Kimura; Shingo Hatakeyama; Kenichi Hata; Takafumi Yanagisawa; Shinya Maita; Shuji Chiba; Hiromi Sato; Soki Kashima; Atsushi Koizumi; Ryohei Yamamoto; Koichiro Takayama; Katsumi Okane; Toshiya Ishida; Yohei Horikawa; Teruaki Kumazawa; Jiro Shimoda; Takehiro Suzuki; Chikara Ohyama; Shin Egawa; Kyoko Nomura; Tomonori Habuchi
Journal:  World J Urol       Date:  2022-02-26       Impact factor: 4.226

2.  Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone.

Authors:  Francesco A Mistretta; Stefano Luzzago; Andrea Conti; Elena Verri; Giulia Marvaso; Claudia Collà Ruvolo; Michele Catellani; Ettore Di Trapani; Gabriele Cozzi; Roberto Bianchi; Matteo Ferro; Giovanni Cordima; Antonio Brescia; Maria Cossu Rocca; Vincenzo Mirone; Barbara A Jereczek-Fossa; Franco Nolè; Ottavio de Cobelli; Gennaro Musi
Journal:  Cancers (Basel)       Date:  2022-05-06       Impact factor: 6.639

Review 3.  Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.

Authors:  Pravien Rajaram; Alyssa Rivera; Kevin Muthima; Nicholas Olveda; Hubert Muchalski; Qiao-Hong Chen
Journal:  Molecules       Date:  2020-05-24       Impact factor: 4.927

4.  Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.

Authors:  Byung Ha Chung; Jian Huang; Zhang-Qun Ye; Da-Lin He; Hirotsugu Uemura; Gaku Arai; Choung Soo Kim; Yuan-Yuan Zhang; Yusoke Koroki; SuYeon Jeong; Suneel Mundle; Spyros Triantos; Sharon McCarthy; Kim N Chi; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2022 Mar-Apr       Impact factor: 3.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.